Physician profile
Mark Mashni
NPI 1902367543
$6,414.34
in general payments reported to CMS, 2019-2025
35 companies · $382 in 2025
The $382 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $1,584 · 2021: $2,520 · 2022: $266 · 2023: $1,008 · 2024: $287 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,183 · Travel and Lodging: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,183.46 |
| Travel and Lodging | $493.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kairos Surgical INC | $2,127.99 | 2020-2021 | |
| Smith+Nephew, INC. | $739.12 | 2020-2025 | Collagenase Santyl, Regranex, Stravix |
| Paragon 28, INC. | $552.38 | 2023 | Portfolio |
| Integra Lifesciences Corporation | $478.45 | 2020-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Stryker Corporation | $401.01 | 2019-2025 | Blueprint Patient Specific Instrumentation |
| Medartis INC. | $377.06 | 2019-2020 | |
| Acumed LLC | $241.51 | 2021 | |
| Organogenesis INC. | $160.72 | 2019-2020 | |
| Kerecis Limited | $138.69 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Depuy Synthes Sales INC. | $136.18 | 2022-2024 | Motoband, Motoband Cp, Fibergraft Bg Morsels |
| Tenex Health INC. | $131.36 | 2021 | |
| Treace Medical Concepts, INC. | $122.34 | 2025 | |
| Nevro Corp. | $105.76 | 2023 | Senza |
| Ossio INC | $103.80 | 2020 | |
| Wright Medical Technology, INC. | $63.42 | 2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $48.44 | 2024-2025 | Qutenza |
| Biotissue Holdings INC. | $46.01 | 2023 | |
| Paratek Pharmaceuticals, INC. | $45.70 | 2023-2024 | Nuzyra |
| Solventum Corporation | $44.28 | 2024-2025 | Prevena, V.A.C. Veraflo, V.A.C.Ulta |
| Kci USA, INC. | $35.48 | 2023 | Activ.A.C. |
| Life Spine, INC. | $34.31 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $32.80 | 2023 | Seglentis |
| Medtronic, INC. | $29.28 | 2023-2024 | Intellis Adaptivestim |
| Cashflow Solutions, LLC | $23.54 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Grt US Holding, INC. | $22.67 | 2021 | |
| Davol INC. | $21.96 | 2025 | Arista |
| Abbvie INC. | $21.66 | 2023 | |
| Polynovo North America LLC | $18.80 | 2025 | Novosorb Btm |
| Extremity Medical | $18.42 | 2019 | |
| Blue Surgical LLC | $17.21 | 2024 | |
| Bioventus LLC | $16.74 | 2022 | |
| Melinta Therapeutics, LLC | $15.90 | 2023 | Kimyrsa |
| Orthofix Medical, INC. | $15.36 | 2025 | Physio-Stim |
| Ibsa Pharma INC. | $15.18 | 2023 | Tirosint, Licart |
| Ets Wound Care LLC | $10.81 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mashni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.